TMS for Migraine: FDA-Cleared Devices and What You Need to Know

Everything you need to know about TMS for Migraine: FDA-Cleared Devices and What You Need to Know — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Migraine is far more than a severe headache. Affecting approximately 1 billion people worldwide and 39 million Americans, migraine is a complex neurological disorder characterized by recurrent attacks of moderate to severe throbbing pain — often on one side of the head — accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Roughly one-third of migraine sufferers experience aura — visual disturbances, sensory changes, or speech difficulties that precede or accompany the headache phase.

Related: TMS in Children and Adolescents · The History of TMS: From Faraday to FDA and Beyond · TMS for Chronic Pain

For many patients, existing treatments are inadequate. Acute medications such as triptans and NSAIDs carry contraindications, side effects, and the risk of medication-overuse headache. Preventive medications — including beta-blockers, anticonvulsants, and CGRP monoclonal antibodies — are not universally effective and often have tolerability issues. Transcranial magnetic stimulation offers a non-pharmacological, generally well-tolerated option.

What You’ll Learn

• Why migraine is a brain-based disorder, not just a vascular headache
• The difference between single-pulse TMS (sTMS) and repetitive TMS for migraine
• Which FDA-cleared TMS devices are available for migraine treatment
• What response rates and outcomes look like from clinical trials
• Whether TMS is the right option for your migraine type

The Neurological Basis of Migraine

Migraine was historically viewed as a vascular disorder, but modern neuroscience has established it as a primary brain disorder involving neural networks, neurotransmitters, and cortical excitability.

The cortical spreading depression (CSD) hypothesis remains central to understanding migraine aura. CSD is a wave of abnormally increased neural activity followed by prolonged suppression of cortical activity that slowly propagates across the brain’s surface. This wave is thought to underlie the visual and sensory phenomena of aura, and it may also trigger the pain pathways that produce the headache phase.

The trigeminal nerve and its associated pain pathways are central to migraine pain generation. The trigeminal nerve innervates the meninges (the protective membranes surrounding the brain), and when activated, it releases inflammatory neuropeptides that cause vasodilation and pain signaling.

The thalamus serves as the relay station for trigeminal pain signals traveling to the cortex, where pain perception occurs. Dysregulation in thalamic pain circuits contributes to the allodynia (pain from normally non-painful stimuli) and photophobia that characterize migraine attacks.

See also: TMS for Alcohol Dependence · TMS for Tinnitus

FDA-Cleared TMS Devices for Migraine

In December 2013, the FDA granted de novo clearance to the first TMS device for migraine, eNeura Therapeutics’ Cerena transcranial magnetic stimulator. It delivers single-pulse transcranial magnetic stimulation (sTMS) and was cleared for the acute treatment of migraine with aura. Later versions of the device (SpringTMS and the sTMS mini) received further 510(k) clearances. Note that eNeura Inc. reportedly filed for bankruptcy in 2020, so check current availability before counting on a specific device.

The clearance was based on a randomized sham-controlled trial in people with migraine with aura. The clearance is for acute treatment of migraine with aura, and the clinical trial enrolled that population.

Single-Pulse vs. Repetitive TMS Protocols

There are two distinct TMS approaches to migraine treatment:

Single-pulse TMS (sTMS) delivers one or a small number of magnetic pulses per session and is designed for acute migraine treatment. Patients use the device at the onset of the aura or headache, delivering pulses to the occipital cortex (the back of the brain). The rationale is that sTMS may interrupt cortical spreading depression or modulate trigeminal pain pathways during an active attack.

Repetitive TMS (rTMS) delivers many pulses over a sustained period and is typically used as a preventive treatment. Protocols for migraine prevention generally involve daily sessions for two to four weeks, targeting the motor cortex or the dorsolateral prefrontal cortex. rTMS is not FDA-cleared for migraine. Small studies suggest it may reduce migraine frequency, but the evidence is limited and protocols are not standardized.

See also: TMS for Depression: What 30+ Clinical Trials Actually Show · Deep TMS vs Standard rTMS: H-Coil vs Figure-8 Coil

Clinical Outcomes and Efficacy

In the randomized sham-controlled trial of sTMS for migraine with aura (Lipton et al., Lancet Neurology, 2010), 39% of patients treated with active sTMS were pain-free at 2 hours, compared with 22% with sham. That is a modest absolute benefit, and many patients did not become pain-free.

For preventive rTMS, the evidence is limited to small trials and reviews with inconsistent results, so no reliable estimate of benefit can be given. It is not a cure, and it is not an FDA-cleared use.

Practical Use of TMS for Migraine

The sTMS device is portable and designed for patient self-administration at home. Patients hold the device against the back of their head at the onset of a migraine attack and trigger a pulse. The treatment takes only a few minutes per session.

Repetitive TMS for migraine prevention requires visits to a clinic or doctor’s office, with daily sessions for two to four weeks followed by maintenance sessions as needed.

See also: Patient Video Testimonials · Accelerated TMS Protocols

Safety and Side Effects

sTMS is remarkably well-tolerated. The most common adverse event is mild transient discomfort at the stimulation site. Because the device delivers only a small number of pulses per session, cumulative side effects are minimal.

rTMS carries slightly more risk, primarily the theoretical risk of seizure induction (as with all rTMS protocols). However, the risk is low with standard protocols, and patients with seizure risk factors are screened out before treatment.

Who Is a Candidate?

TMS for migraine is most appropriate for:

• Patients with migraine with aura who want to avoid or cannot tolerate acute medications
• Patients with medication-overuse headache who need a non-pharmacological option
• Patients with contraindications to triptans (such as cardiovascular disease)
• Patients seeking to reduce reliance on preventive medications

For migraine patients who have struggled to find effective treatment, single-pulse TMS is an FDA-cleared option for acute treatment of migraine with aura, with fewer drug-type side effects, though its benefit is modest.